BioMarin Pharmaceutical | BMRN - Cost Of Sales

Stock Price
53.81
Daily Change
0.51 0.96%
Monthly
-1.79%
Yearly
-15.51%
Q2 Forecast
52.04

BioMarin Pharmaceutical reported $161.56M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
Bayer EUR 4.5B 194M Dec/2025
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Insmed USD 46.16M 15.25M Dec/2025
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Moderna USD 452M 245M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.76B 344M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025